ETN029

ETN029 is a DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research[1].

Product Specifications

CAS Number

[3066864-32-9]

UNSPSC

12352005

Target

Notch

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@H](C(N([C@H](C(N[C@@H]3C(N[C@@H](CC4CCN(CC(O)=O)CC4)C(N[C@@H](CC(N)=O)C(N[C@@H](CC5=CC=C6C=CC=CC6=C5)C(N[C@@H](CCCCNC(CN7CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC7)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N8CCC[C@H]8C(N)=O)=O)CC9=CNC%10=C9C=CC=C%10)=O)CSCSC3)=O)=O)=O)=O)=O)=O)=O)CC(C)(C)C)C)=O)[C@@H](C)O)=O)=O

Molecular Formula

C101H140N22O26S2

Molecular Weight

2142.45

References & Citations

[1]Chunhui Huang, et al. ETN029: Discovery and development of a DLL3-targeting radioligand therapy for the treatment of SCLC and beyond. ACS. 2025 Aug 20.